1005203-16-6Relevant articles and documents
2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3β with good brain permeability
Saitoh, Morihisa,Kunitomo, Jun,Kimura, Eiji,Iwashita, Hiroki,Uno, Yumiko,Onishi, Tomohiro,Uchiyama, Noriko,Kawamoto, Tomohiro,Tanaka, Toshimasa,Mol, Clifford D.,Dougan, Douglas R.,Textor, Garret P.,Snell, Gyorgy P.,Takizawa, Masayuki,Itoh, Fumio,Kori, Masakuni
, p. 6270 - 6286 (2009)
Glycogen synthase kinase 3β (GSK-3β) inhibition is expected to be a promising therapeutic approach for treating Alzheimer's disease. Previously we reported a series of 1,3,4-oxadiazole derivatives as potent and highly selective GSK-3β inhibitors, however,
